Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Gaudet

Showing results (261-270 of 304) with videos related to

Pageof 31
Sort By:
Diabetes|April 30, 2002
5' flanking variants of resistin are associated with obesityJames C Engert, Marie-Claude Vohl, Scott M Williams, et al.
Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.
Atherosclerosis|September 12, 2020
No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levelsKang H Zheng, Yannick Kaiser, Casper C van Olden, et al.
The New England Journal of Medicine|August 20, 2020
Evinacumab for Homozygous Familial HypercholesterolemiaFrederick J Raal, Robert S Rosenson, Laurens F Reeskamp, et al.
Nature Medicine|August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohortsGerald F Watts, Christian Schwabe, Russell Scott, et al.
The New England Journal of Medicine|September 1, 2020
Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The Lancet. Diabetes & Endocrinology|September 8, 2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCTRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
Nature Medicine|March 6, 2023
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trialRobert S Rosenson, Daniel Gaudet, Christie M Ballantyne, et al.
NEJM Evidence|February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in HypertriglyceridemiaDaniel Gaudet, Peter Clifton, David Sullivan, et al.
Journal of Clinical Lipidology|January 28, 2024
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemiaZobaida Al-Baldawi, Leslie Brown, Isabelle Ruel, et al.
Pageof 31

Showing results (261-270 of 304) with videos related to

Sort By:
Pageof 31
Diabetes|April 30, 2002
5' flanking variants of resistin are associated with obesityJames C Engert, Marie-Claude Vohl, Scott M Williams, et al.
Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.
Atherosclerosis|September 12, 2020
No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levelsKang H Zheng, Yannick Kaiser, Casper C van Olden, et al.
The New England Journal of Medicine|August 20, 2020
Evinacumab for Homozygous Familial HypercholesterolemiaFrederick J Raal, Robert S Rosenson, Laurens F Reeskamp, et al.
Nature Medicine|August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohortsGerald F Watts, Christian Schwabe, Russell Scott, et al.
The New England Journal of Medicine|September 1, 2020
Evolocumab in Pediatric Heterozygous Familial HypercholesterolemiaRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
The Lancet. Diabetes & Endocrinology|September 8, 2022
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCTRaul D Santos, Andrea Ruzza, G Kees Hovingh, et al.
Nature Medicine|March 6, 2023
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trialRobert S Rosenson, Daniel Gaudet, Christie M Ballantyne, et al.
NEJM Evidence|February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in HypertriglyceridemiaDaniel Gaudet, Peter Clifton, David Sullivan, et al.
Journal of Clinical Lipidology|January 28, 2024
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemiaZobaida Al-Baldawi, Leslie Brown, Isabelle Ruel, et al.
Pageof 31